Company intelligence / Profile preview
WiNK Therapeutics
Miami, Florida, United Stateswinktx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Successfully tested impact on human insulin-producing islet cells engrafted in mice, showing regeneration of human islet cells and expression of proteins that protect cells from autoimmune attack. Planning preclinical validation studies for FDA approval, with hopes for Phase 1 clinical trial approval for diabetes in the next two years (as of December 2024)[1][2]
- Therapeutic areas
- OncologyEndocrinology
- Modalities
- RNA aptamersmodified RNA therapeutics
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on WiNK Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WiNK Therapeutics.